Hello, Guest!

Welcome to MS Money Moves!

Biotech stock research and education made easy!

Save Time and Gain an Edge!

How It Works

MS gives you an edge and saves you time. We do this through our expert insights in biotech delivered via Email, SMS alerts, and our website
The days of needing a Ph.D & taking weeks to research investments is over! 
*We have a team standing by to help answer subscribers questions!
howitworks
*Subscribers portfolio following our service

Recent Wins

First mentioned in article, reaffirmed in nightly email
Article: Nov 17th Click image to read article
Researched released around $6 per share in November, updates provided since
Outlined in nightly email 5/18/20 ran past $25 by end of August

Compehrensive Performance statistics coming soon!

What Our Subscribers Say About US

Team

The MS executive team has extensive experience between them and complimentary skill sets gained through actively investing in the biotech industry. Over the years they have developed a strategy and fine-tuned research methods, yielding returns that have proven to outpace the market and many analysts. 

Zion Miller

CEO & Co Founder
                 

Sultan Beardsley

COO & Co Founder
        

Chris Stang

CPO 
        

Michael Lipari

Advisor
     

Travis Kellerman

Advisor
            

Research

Updated Every Night!

This is our nightly email which includes the following for our community;

  1. > Market updates, what happened in the previous session, what’s forecasted to happen tomorrow
  2.  > 4-5 researched tickers with bullet points on their story and how we might plan to trade them. Includes a price target
  3. > Click below to see last nights email
BioCryst Pharmaceuticals (Nasdaq: BCRX): Embarrassment of Riches

May 27, 2020 by Sultan Beardsley

Over the years BCRX has successfully commercialized multiple products including Peramivir injection for influenza and Mundesine for Peripheral T-cell lymphoma (PTCL). While Peramivir and Mundasine are valuable in their own respects, it is Berotralstat (now called Orladeyo), BCX9930, Galidesivir, and BCX9250 that are central to our discussion of BCRX’s embarrassment of riches. Ultimately, in our view, BCRX is one of the most misunderstood biotech stocks of 2020 and on the cusp of a significant transformation and growth.

SMS Alerts

Guidelines For SMS Alerts *We send on average 1-2 per day

  • >We like to use 1-5% of our account value for day & or swing trades
  • >Price targets are estimates. Do not be deterred from selling before it is hit if you are in the green (have made a profit) on the position. Sometimes stocks run past the price we send a sell alert. 
  • >Consider stop losses even if not mentioned. Generally, stop losses are best set a percent below the first major support level (ask if you are unsure what this is).
  • >Cut losses quick if the trend changes
  • >Do not trade when feeling emotional or pressured to make back losses
  •  

Disclaimer

MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.

The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.